(3S,4S)-3-hexyl-4-[(2R)-2hydroxytridecyl]oxetan-2-one | 104872-07-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (3S,4S)-3-hexyl-4-[(2R)-2hydroxytridecyl]oxetan-2-one
• 英文别名: tetrahydroesterastin；rac-3-hexyl-4-(2-hydroxy-tridecyl)-2-oxetanone；3,5-dihydroxy-2-hexyl-hexadecanoic 1,3-lactone；3-Hexyl-4-(2-hydroxytridecyl)oxetan-2-one
• CAS: 104872-07-3
• 化学式: C₂₂H₄₂O₃
• 分子量: 354.574
• InChiKey: RSOUWOFYULUWNE-UHFFFAOYSA-N

物化性质

• 溶解度：
  可溶于氯仿、可溶于二氯甲烷、乙酸乙酯

计算性质

• 辛醇/水分配系数(LogP)：
  8.3
• 重原子数：
  25
• 可旋转键数：
  17
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (3S,4S)-3-hexyl-4-[(2R)-2hydroxytridecyl]oxetan-2-one 、 1-溴-3-氯丙烷 在 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 生成 5-(3-chloropropanyloxy)-2-hexyl-hexadecanoic 1,3-lactone
  参考文献：
  名称：

  Oxetanone derivatives

  摘要：

  本发明涉及一种新型氧杂环戊酮衍生物化合物及其生产方法，该衍生物可用作脂肪酶抑制剂。此外，本发明还涉及生产盐和药物组合物的方法，该组合物包括至少一种氧杂环戊酮衍生物或盐，以及使用该化合物和组合物抑制脂肪酶的方法。

  公开号：

  US06348492B1

文献信息

• N-acyl modified polysaccharides and pharmaceutical compositions comprising same
  申请人：Gentry Mullins Jason John

  公开号：US20060046974A1

  公开（公告）日：2006-03-02

  This invention relates to novel N-acyl modified polysaccharides and pharmaceutical compositions comprising the modified polysaccharides. Further the invention relates to processes for using such compounds to inhibit lipases, to lower cholesterol, to lower the absorption of dietary fat, or as a dietary fiber supplement. In a preferred aspect of the invention the modified polysaccharides are capable of absorbing substantial amounts of oils or fats while dissipating in an aqueous solution. The invention also relates to a non-absorbable and essentially non-digestible polysaccharide fiber composition.

  本发明涉及新型的N-酰基修饰多糖和包含修饰多糖的药物组合物。此外，本发明还涉及使用这些化合物抑制脂肪酶、降低胆固醇、降低膳食脂肪吸收或作为膳食纤维补充剂的方法。在本发明的一个优选方面，修饰多糖能够吸收大量油脂，同时在水溶液中消散。本发明还涉及一种不可吸收且基本上不可消化的多糖纤维组合物。
• PROCESS FOR MAKING (2S, 3S, 5S) OXETANONE DERIVATIVES
  申请人：——

  公开号：US20020045767A1

  公开（公告）日：2002-04-18

  This invention relates to novel processes for making (2S, 3S, 5S) oxetanone derivative lipase inhibitor compounds and intermediates therefor, which processes for producing such derivatives that are useful as lipase inhibitors are capable of being scaled to commercial quantities. Further the invention relates to processes for producing salts and for producing pharmaceutical compositions compounds comprising at least one such oxetanone derivative or salt, as well as methods for using such compounds and compositions for inhibiting lipases.

  本发明涉及一种制备(2S,3S,5S)氧杂环己酮衍生物脂肪酶抑制剂化合物及其中间体的新工艺，这些用于生产这种衍生物的工艺能够扩展到商业规模，其制备的衍生物可用作脂肪酶抑制剂。此外，本发明还涉及制备盐和制备含有至少一种这种氧杂环己酮衍生物或盐的药物组合物的工艺，以及使用这些化合物和组合物抑制脂肪酶的方法。
• Process for making (2S, 3S, 5S) oxetanone derivatives
  申请人：——

  公开号：US20020058822A1

  公开（公告）日：2002-05-16

  This invention relates to novel processes for making (2S, 3S, 5S) oxetanone derivative lipase inhibitor compounds and intermediates therefor, which processes for producing such derivatives that are useful as lipase inhibitors are capable of being scaled to commercial quantities. Further the invention relates to processes for producing salts and for producing pharmaceutical compositions compounds comprising at least one such oxetanone derivative or salt, as well as methods for using such compounds and compositions for inhibiting lipases.

  本发明涉及制备（2S, 3S, 5S）氧杂环戊酮衍生物脂肪酶抑制剂化合物及其中间体的新工艺，用于生产这些衍生物的工艺能够扩大到商业规模，这些衍生物是有用的脂肪酶抑制剂。此外，本发明还涉及制备盐和制备至少包含一种这样的氧杂环戊酮衍生物或盐的药物组合物的工艺，以及使用这些化合物和组合物抑制脂肪酶的方法。
• Novel method for the asymmetric synthesis of beta-lactone compounds
  申请人：Smith W. Jeffrey

  公开号：US20060258620A1

  公开（公告）日：2006-11-16

  The present invention features methods of treating a cancer in a subject by administering an effective amount of a beta-lactone to the subject. The invention also features methods of inhibiting angiogenesis in a subject by administering an effective amount of an inhibitor of fatty acid synthase to the subject. These methods can be used to treat a variety of cancers and other diseases and conditions. The invention also features methods of identifying beta-lactones and other compounds that can be used in the methods of the invention for the treatment of tumors, inhibition of angiogenesis, and the treatment of diseases and conditions that involve pathological angiogenesis. The invention also features methods of synthesizing beta-lactones and features novel beta-lactone compounds.

  本发明涉及通过向患者施用有效量的β-内酰胺来治疗患者身上的癌症的方法。本发明还涉及通过向患者施用脂肪酸合成酶抑制剂的有效量来抑制患者身上的血管生成的方法。这些方法可以用于治疗各种癌症和其他疾病和病况。本发明还涉及识别β-内酰胺和其他化合物的方法，这些化合物可以用于本发明中用于治疗肿瘤、抑制血管生成以及治疗涉及病理性血管生成的疾病和病况的方法。本发明还涉及合成β-内酰胺的方法和新型β-内酰胺化合物的特点。
• NOVEL METHOD FOR THE ASYMMETRIC SYNTHESIS OF BETA-LACTONE COMPOUNDS
  申请人：Smith Jeffrey W.

  公开号：US20100173982A1

  公开（公告）日：2010-07-08

  The present invention features methods of treating a cancer in a subject by administering an effective amount of a beta-lactone to the subject. The invention also features methods of inhibiting angiogenesis in a subject by administering an effective amount of an inhibitor of fatty acid synthase to the subject. These methods can be used to treat a variety of cancers and other diseases and conditions. The invention also features methods of identifying beta-lactones and other compounds that can be used in the methods of the invention for the treatment of tumors, inhibition of angiogenesis, and the treatment of diseases and conditions that involve pathological angiogenesis. The invention also features methods of synthesizing beta-lactones and features novel beta-lactone compounds.

  本发明涉及通过向受试者施用有效量的β-内酰胺来治疗癌症的方法。本发明还涉及通过向受试者施用脂肪酸合成酶抑制剂的有效量来抑制血管生成的方法。这些方法可用于治疗各种癌症和其他疾病和病况。本发明还涉及识别β-内酰胺和其他化合物的方法，这些化合物可用于本发明的治疗肿瘤、抑制血管生成以及涉及病理性血管生成的疾病和病况的方法。本发明还涉及β-内酰胺的合成方法和新型β-内酰胺化合物。